Clinical Trial Update: A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial is evaluating the safety and activity of SAR448501/DR-0201 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, and the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• SAR448501/DR-0201

Snippet

Sponsor: Sanofi | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: RECRUITING